Oxford Instruments Asylum Research Opens an AFM Demonstration Lab in Mumbai
Oxford Instruments Asylum Research announces the opening of its first Nanotechnology Lab for Atomic Force Microscopy (AFM) in India. The new lab is located at the Oxford Instruments India headquarters in Mumbai and adds to the range of industrial analysis tools available for demonstration. The lab is staffed by a dedicated business manager, Manju Kumar, and AFM applications scientist, Kishore Kumar.
This lab is an initiative to meet this commitment and provide the same high standard of service to Indian researchers.
Asylum Research is known for their technology leadership in AFM, ranging from the affordable MFP-3D Origin AFM to the most advanced Cypher ES, the highest resolution fast scanning AFM that also features full environmental control. Leading research laboratories around for world choose Asylum Research AFMs for applications ranging from materials research to bioscience because of their high performance, versatility, and unmatched customer support. The goal of the new AFM lab in India is to help researchers choose the best AFM for their research and then provide them with exceptional customer support from the knowledgeable local sales and applications team.
The AFM Lab in India is equipped with the MFP-3D™ Classic and the MFP-3D Origin™ for demonstration. The MFP-3D Origin, the most affordable member, offers high performance equal to the MFP-3D Classic and an impressive selection of options and operating modes. It also offers full upgrade potential. The MFP-3D Classic offers maximum versatility with the widest range accessories for nanomechanical and nanoelectrical characterisation and powerful environmental control capabilities.
31568pr@reply-direct.com
Reprocell Acquires 3D Cell Culture Company Reinnervate Ltd and Human Tissue Supplier BioServe
Reinnervate Ltd has been acquired by Reprocell of Shin-Yokohama in Japan. Reprocell, a pioneer in the field of induced pluripotent stem cell biology supplies iPSC-dervided Hepatocytes, Neurons and Cardiomyocytes as well as a range of media and reagents for stem cell culture.
Reprocell intends to combine its iPSC-derived cells with the Alvetex range of 3D cell culture products to produce and sell next-generation tools for drug toxicity testing, neuroscience and cancer research.
Reprocell also announced the acquisition of BioServe Inc of MD, USA, a leading supplier of human tissues and other biological samples with one of the largest commercial biorepositories in the world.
Reprocell plans to use the unparalleled access to human tissues to generate a wide range of disease-related iPSC lines for production of human disease cell models.
Commenting on the deal, Reinnervate Ltd CEO. Richard Rowling, said “We are delighted to become part of the Reprocell group of companies and look forward seeing Alvetex products combined with Reprocell’s advanced stem cell derived cell products. Our customers are always looking for ways to improve the biological relevance of cell based assays and to move away from using cell lines. Combining the benefits offered by iPSC-derived cells and 3D cell culture will lead to exciting new product introductions.”
Chika Yokoyama, CEO of Reprocell added, “The Reprocell group of companies now offers products and services that span the 2D and 3D cell culture, stem cell culture media, iPSC-derived cells and human tissue samples. We can now help the global scientific community move their basic and pre-clinical research towards more sustainable and physiologically relevant models. Our customers can now move easily from testing monolayer culture to 3D culture to human tissue systems all with support from a single source.”
31569pr@reply-direct.com
ACM Global Central Laboratory Officially Opens New Shanghai Lab Facility
ACM Global Central Laboratory, a diagnostic central laboratory delivering high-quality testing services that optimise clinical trial outcomes, today announced the official opening of its recently acquired Shanghai lab facility. ACM Shanghai is an element of ACM Global’s acquisition of Phoenix Pharma Central Services Pte Ltd (Phoenix PCS), a premier central laboratory services provider for Asia-Pacific clinical trials. Leveraging existing staff and local knowledge from Phoenix PCS, the fully-operational lab enables ACM Global to provide support of clinical trials throughout Shanghai and beyond with increased speed and efficiency.
“The opening of our wholly-owned Shanghai lab facility follows the successful launch of ACM Singapore in June, further extending ACM Global’s network of operating labs in an increasingly important region for clinical research,” said Jerry Boxall, Managing Director, ACM Europe and Asia.
ACM Shanghai is 10,000ft2 in size and located within the Shanghai International Medical Zone of the city’s Pudong district. The purpose- designed lab facility houses cutting-edge instruments and equipment identical to ACM’s US and UK laboratories and provides a broad menu of safety and specialty testing, including chemistry, haematology, urinalysis, and immunology testing. Lee Chiew Yan, PhD, FRCPath, who joined ACM Global from Phoenix PCS as Director, Singapore and China Operations, oversees both the ACM Shanghai and Singapore facilities, including all staff and operations. She brings more than 20 years of experience in central laboratory operations within the Asia-Pacific region.
31658pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144
